Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness 
Uber Stock Falls as Waymo Plans to End Robotaxi Partnership by 2028 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
GE Vernova Q2 Revenue Tops Estimates as Earnings Miss, Shares Slide Despite Higher 2026 Outlook 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand 
OpenAI AI Agent Reportedly Breached Hugging Face, Raising AI Safety Concerns 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Samsung Eyes Up to $1.14 Billion Investment in AI Startup Mistral 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
SpaceX Stock Slump Wipes Out Nearly $700 Billion From Elon Musk’s Paper Wealth 
Oracle Stock Rises After Winning Up to $6.99 Billion U.S. Defense Software Contract 
Amkor Stock Surges 17% After $1.5 Billion Nvidia AI Packaging Partnership 
Trump Administration Monitors OpenAI Incident as Lawmakers Push AI Kill Switch Bill 
CAMBRIDGE, Mass., Feb. 09, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.
Cellaria's unique patient-specific cell models and cell culture media products expand the current offering AMSBIO has for physiologically relevant cell culture products for drug discovery and other life science applications. Late in 2016, Cellaria announced the availability of new models for High Grade Serous and Endometriod Ovarian Cancer and an ER-positive breast model.
AMSBIO is a premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. As a leading provider of scaffolds, matrices, kits and proteins for growing and screening spheroids and organoids, AMSBIO has contributed to the acceleration of discovery programs in medical research.
Alex Sim, managing director at AMSBIO said, "The new partnership with Cellaria expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision medicine.”
"The unique value of our patient-specific cell models makes AMSBIO an ideal partner for Cellaria," said David Deems, chief executive officer at Cellaria. "Our products will expand the AMSBIO cancer product portfolio, and their technical expertise will enable them to support Cellaria's customers throughout Europe."
About Cellaria
Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient's needs. Cellaria's innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visit www.cellariabio.com or to learn more about our cell models.
Contact: Tim Walsh for Cellaria Bio 617.512.1641 [email protected]
